About B-cell lymphoma 3 protein
B-cell lymphoma 3 protein (BCL3) is a protein
from Homo sapiens identified by UniProt accession
P20749, 454 residues long.
MolForge cross-references it against 0 known binders and
520 disease associations.
Target properties
| Protein name | B-cell lymphoma 3 protein |
| UniProt accession | P20749 |
| Gene | BCL3 |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (520)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- colon adenocarcinoma · score 0.37
- bile duct carcinoma · score 0.37
- colorectal adenocarcinoma · score 0.37
- eosinophil count · score 0.33
- high density lipoprotein cholesterol measurement · score 0.31
- low density lipoprotein cholesterol measurement · score 0.31
- skin basal cell carcinoma · score 0.30
- hepatocellular carcinoma · score 0.29
- melanoma · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P20749-F1 | alphafold | PREDICTED | 71.34 | — |
Amino-acid sequence (454 residues)
MPRCPAGAMD EGPVDLRTRP KAAGLPGAAL PLRKRPLRAP SPEPAAPRGA AGLVVPLDPL RGGCDLPAVP GPPHGLARPE ALYYPGALLP LYPTRAMGSP FPLVNLPTPL YPMMCPMEHP LSADIAMATR ADEDGDTPLH IAVVQGNLPA VHRLVNLFQQ GGRELDIYNN LRQTPLHLAV ITTLPSVVRL LVTAGASPMA LDRHGQTAAH LACEHRSPTC LRALLDSAAP GTLDLEARNY DGLTALHVAV NTECQETVQL LLERGADIDA VDIKSGRSPL IHAVENNSLS MVQLLLQHGA NVNAQMYSGS SALHSASGRG LLPLVRTLVR SGADSSLKNC HNDTPLMVAR SRRVIDILRG KATRPASTSQ PDPSPDRSAN TSPESSSRLS SNGLLSASPS SSPSQSPPRD PPGFPMAPPN FFLPSPSPPA FLPFAGVLRG PGRPVPPSPA PGGS
Explore B-cell lymphoma 3 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets